Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06108726 | A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | Phase 2 | 16 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06104709 | Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma | unknown | — | 10 | China-Japan Friendship HospitalOTHER | 0 | Oct 27, 2023 |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06081777 | Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer(MRDinS3LC) | unknown | — | 65 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04737382 | Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.(OSIRIS) | unknown | N/A | 200 | The Netherlands Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06068088 | Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)(LUNGDIET) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 5, 2023 | clinicaltrials |
| NCT06065813 | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04726215 | Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | unknown | Phase 2 | 50 | CellSight Technologies, Inc.INDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05273047 | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC(LungKG12Ci) | unknown | — | 458 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04074993 | Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | unknown | Phase 2 | 35 | JI-YOUN HANOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05128630 | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.(DEDALUS) | unknown | Phase 2 | 45 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05999214 | 99mTc-H7ND SPECT/CT Imaging in NSCLC | unknown | N/A | 150 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06018688 | Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | unknown | Phase 2 | 44 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT05418660 | Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC(I-STOP) | unknown | — | 300 | University of Milano BicoccaOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06031597 | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | unknown | Phase 3 | 105 | Zhejiang Cancer HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03334864 | Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG) | unknown | — | 5,000 | Peking Union Medical College HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05338619 | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy(PLATINUM) | unknown | Phase 2 | 77 | Sung Yong LeeOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020989 | Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy(CHAMELEON) | unknown | Phase 2 | 129 | Yonsei UniversityOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020352 | The Efficacy and Safety of KN046 Combined With Axitinib | unknown | Phase 2 / Phase 3 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06014450 | Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study | unknown | N/A | 144 | Guizhou Medical UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05869162 | Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI | unknown | Phase 2 | 153 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06010277 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX) | unknown | Phase 4 | 50 | Amphia HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05892237 | CIETAI and Sequential Radiotherapy in Squamous Lung Cancer | unknown | Phase 2 | 50 | Dong WangOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05347628 | Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 91 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03215693 | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | unknown | Phase 2 | 152 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05991895 | Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer | unknown | — | 5,000 | Jinming YuOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05102214 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05978401 | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 152 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05974007 | Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC(NeoR-World) | unknown | — | 1,500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05962021 | Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 126 | Peking University People's HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05648955 | Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment(ALLIES) | unknown | Early Phase 1 | 118 | Nutricia ResearchINDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05965102 | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer | unknown | Phase 1 | 31 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05794711 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05794724 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05094882 | Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010) | unknown | — | 500 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05932264 | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05925738 | Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer | unknown | — | 1,500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05925751 | Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05921474 | Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors(SABR-DETECT) | unknown | — | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05919641 | LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT(LIVELUNG) | unknown | — | 130 | Odense University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05489731 | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer(VIC-1911) | unknown | Phase 1 | 72 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.OTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05900219 | Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study | unknown | Phase 2 | 75 | Shanghai Kechow Pharma, Inc.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05527808 | A Single-arm Exploratory Study of Neoadjuvant Therapy | unknown | N/A | 28 | Jun LiuOTHER | 1 | Jun 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 31, 2023source: clinicaltrials